Table 2.
T 1 sensitivity and specificity tables for changes in RIF-1 tumour volume following everolimus or patupilone treatment
|
A. Everolimus: using a ΔT1 of −8% | |||
| |
ΔTVol |
|
|
|
ΔT
1
|
Positive |
Negative |
Total |
|
Positive |
5 |
3 |
8 |
|
Negative |
0 |
5 |
5 |
|
Total |
5 |
8 |
13 |
|
B. Patupilone: using a ΔT1 of −8%. | |||
| |
ΔTVol |
|
|
|
ΔT
1
|
Positive |
Negative |
Total |
|
Positive |
7 |
3 |
10 |
|
Negative |
0 |
10 |
10 |
| Total | 7 | 13 | 20 |
A. Everolimus: The prevalence (total positive/all) = 0.38. The sensitivity =1.0 and the 1- specificity = 0.38, giving a positive prediction value of 0.63 and a negative prediction value of 1.0 at this ΔT1 cut-off of −8%.
B. Patupilone: The prevalence (total positive/all) = 0.35. The sensitivity =1.0 and the 1- specificity = 0.23, giving a positive prediction value of 0.70 and a negative prediction value of 1.0 at this ΔT1 cut-off of −8%.